There are currently 54 clinical trials in Tamarac, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Novartis investigative site, West Broward Rheumatology Associates, Inc. and Oncology & Hematology Associates of West Broward. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
NCT05862272
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Tamarac, Tamarac, Florida
Conditions: Uterine Fibroids, Endometriosis
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Tamarac, Florida
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
NCT05859724
Recruiting
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/09/2024
Locations: D&H Tamarac Research Center, Tamarac, Florida
Conditions: Atopic Dermatitis
Register for Updates
A Clinical Investigation Evaluating Wound Closure With OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's
NCT05193929
Recruiting
The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation in the venules and arterioles. Fibracol Plus (or equivalent) is a collagen alginate dressing that is used as the primary dressing. Both products are 510(k) FDA cleared and will be used within the cleared intended use. Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Integral Clinical Trials Solutions, Tamarac, Florida
Conditions: Diabetic Foot Ulcer
Register for Updates
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: BRCR Medical Center Inc., Tamarac, Florida
Conditions: Advanced Solid Tumor
Register for Updates
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
NCT05660265
Recruiting
This will be a first time in human (FTIH) study in sickle cell diseases (SCD) participants. The FTIH study is planned to evaluate the safety, tolerability, and pharmacokinetics of GSK4172239D. The study will be composed of 3 periods for all participants (Screening, Treatment, and Follow up). Participants will be screened and, prior to first dose on Day 1, will be randomized to receive either GSK4172239D or placebo. GSK4172239D is a prodrug that is converted in vivo into GSK4106401. This study... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
11/06/2023
Locations: GSK Investigational Site, Tamarac, Florida
Conditions: Hematologic Diseases, Anaemia, Sickle Cell
Register for Updates